sequent cycle. Upon completion of her treatment she was in Keywords: AML; MDS; monosomy 7; 11q23 translocation complete remission but continued to have persistent pancytopenia; she was treated with erythropoietin and rhG-CSF without improvement and required frequent transfusions. A bone Introduction marrow aspirate and biopsy 4 months after cessation of chemotherapy revealed marrow hypoplasia with dyserythroSecondary acute myelocytic leukemia (AML) and myelodyspoiesis, no excess of blasts, and monosomy 7 (19 out of 20 plastic syndromes (MDS) are a known complication in metaphases). At this point she was referred to our center for patients previously treated with different chemotherapeutic an allogeneic BMT from her HLA-matched sibling. As part of regimens. Administration of alkylating agents with or without her pre-BMT work-up, a repeated karyotype analysis was radiation therapy have been implicated in the pathogenesis of done and only two out of 30 metaphases had the monosomy therapy-related AML/MDS (t-AML/MDS).
complete remission but continued to have persistent pancytopenia; she was treated with erythropoietin and rhG-CSF without improvement and required frequent transfusions. A bone Introduction marrow aspirate and biopsy 4 months after cessation of chemotherapy revealed marrow hypoplasia with dyserythroSecondary acute myelocytic leukemia (AML) and myelodyspoiesis, no excess of blasts, and monosomy 7 (19 out of 20 plastic syndromes (MDS) are a known complication in metaphases). At this point she was referred to our center for patients previously treated with different chemotherapeutic an allogeneic BMT from her HLA-matched sibling. As part of regimens. Administration of alkylating agents with or without her pre-BMT work-up, a repeated karyotype analysis was radiation therapy have been implicated in the pathogenesis of done and only two out of 30 metaphases had the monosomy therapy-related AML/MDS (t-AML/MDS). 1 These patients usu-7 (the other 28 cells had a normal karyotype). Two follow-up ally have a latent period of over 5 years and partial deletions studies at 2-month intervals failed to demonstrate the presence or complete loss of chromosomes 5 or 7. More recently, tof any monosomy 7 with all metaphases having a normal AML/MDS with translocations involving chromosome 11 46,XX karyotype (no excess of blasts was noticed). The disap-(band q23) has been reported after therapy with DNA-topoisopearance of the karyotypic abnormality was accompanied by merase II inhibitors. 2 These patients differ from those with a normalization of her peripheral blood count from an initial monosomy 7 by having a shorter latency and evolution into WBC 1.9 × 10 −3 /mm 3 , hemoglobin 7.1 g%, platelets monocytic or myelomonocytic leukemias. Bone marrow transplants from unrelated donors for leuToxicity kaemias are increasing greatly in number and also in proportion to matched sibling donor transplants. The panel has
Increasing age and degree of mismatch each increase the considered unrelated donor transplant (UD-BMT) on the basis probability of transplant-related mortality and morbidity and of efficacy, toxicity and indications in leukaemias. The conneed to be taken into account when assessing the use of UDclusions and statements are based largely but not exclusively BMT in any situation. In young (less than 20 years) good risk on information provided at the Consensus Conference.
patients, the mortality of the procedure is of the order of 15%, which rises in older patients (at 45 years to 30% or more).
Transplants with an HLA mismatched (A, B or DR) marrow Efficacy have a high toxicity compared with matched marrow and cannot be equated with sibling transplants. Unrelated bone marrow transplants for some types of leuThere are, to date, few published studies concerning quality kaemia can produce prolonged quiescence and, in some of life in recipients of UD-BMT. In order to inform decision cases, eradication of disease.
making, such information must be collected using well valiData based on serologically matched donors at HLA A, B dated standardised tests. and DR suggest that matched unrelated transplants may have similar survival to sibling transplants in comparable disease states. This is accepted as a reasonable statement but begs the question of what is implied by 'matched' in unrelated transplants. Much of the data concerning the survival and toxicity Indications in unrelated transplants has come from studies using serological typing. The effect of molecular typing on outcome may alter indications.
Information which allows the classification of various diseases into good, standard and high risk is essential in allowing comInformation on the place of sibling transplants compared with chemotherapy and autologous transplants in the manageparative assessment of treatments including UD-BMT. Evidence suggests that the results of UD-BMT are better ment of some leukaemias has been provided by randomised studies organised by the EORTC and the MRC. These define when performed early in some diseases. The timing of UD-BMT, however, depends on the consideration of other treatthe place of sibling bone marrow transplantation in the management of acute leukaemias. Conclusions drawn from these ment options.
For patients with CML in chronic phase or accelerated studies on the presence or absence of benefit of sibling transplants may apply to unrelated transplants.
phase, UD-BMT should be considered as the best available treatment at present for patients without a matched sibling In a few situations, the evidence for efficacy is based on the level 1 documentation of zero survival following conventional donor providing that the unrelated donor provides a 'close match' (level 1c evidence). therapy but with some survivors following transplant (eg childhood ALL with early bone marrow relapse). However, in situFor patients with AML in first remission, UD-BMT has little place at the present time. In second CR, it may be considered, ations where alternative therapies occasionally succeed, level 1 evidence from randomised trials is rarely available to help though its role in relation to other therapies requires further evaluation. UD-BMT has a clear place in a subgroup of in decision making.
There is variation in outcome reported from different patients with initial refractory disease, secondary AML and high risk myelodysplastic syndromes (level 1c evidence). sources for particular conditions. In part, this may be because subdivisions of different types of leukaemia are not always For a small group of children with very high risk ALL in first remission, and for children in second remission who have accurately defined. Attempts to identify subgroups and to compare 'like with like' are essential even though they make sustained an early bone marrow relapse, data suggest that survival may be improved by UD-BMT (level 1c evidence). Simidata collection and comparisons more arduous.
It is important that rigorous economic evaluations and lar criteria may apply to adult ALL but present data are even more limited. quality of life studies are carried out alongside 'like with like' comparisons.
The results of UD-BMT for desperate disease (such as CML in blast crisis or acute leukaemia in overt relapse) are discouraging (10% or less survival) and are associated with marked and often unquantitated toxicity. It may be considered that toxicity inflicted on the unsuccessful recipients negates the ful in terms of survival.
Information for decision-making
Policies on anonymity differ widely throughout the world. There are good reasons to maintain strict anonymity between donor and recipient despite theoretical problems in donor UD-BMT should only be carried out where there are facilities recruitment. The potential problems of breaking this anonyfor full characterisation of the recipient's disease, molecular mity seem to outweigh the benefits of disclosure. Systematic HLA typing available and guaranteed reporting to national or investigation of these matters should be carried out. international registries.
Further research addressing the complex ethical and psyFor conditions where there is no level 1 evidence and there chosocial issues surrounding related and unrelated donors, is doubt about the benefits of UD-BMT vs other therapies, the should be undertaken. procedure is only justified as part of a randomised trial (or formal pilot for such a trial).
With respect to more general planning of services it is Scientific organising committee important to research the issue of whether UD-BMT should take place in a limited number of specialised units.
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LETTERS TO THE EDITOR

Human T cell leukemia/lymphoma virus type I (HTLV-I) and Pneumocystis carinii associated with T cell proliferation and haemophagocytic syndrome
Haemophagocytic syndrome (HPS) is a rare disorder characsyndrome, with liver, marrow and lung infiltration with CD3 + CD57 + T cells. terized by fever, pancytopenia, liver dysfunction and proliferation of mature, cytologically benign, haemophagocytic histi-HTLV-I has not so far been described with HPS. P. carinii has been associated with HPS only when complicating HIV ocytes and often fatal outcome. It is now recognised that HPS can be initiated by various causes including viruses infection. P. carinii rarely complicates HTLV-I infection and, if so, is considered predictive of ATL. 2 Two studies reported (cytomegalovirus, Epstein-Barr virus, herpes simplex virus) bacteria, fungi and parasites (particularly P. carinii in HIVlarge granular cell (LGL) or aggressive natural killer leukemia associated with HPS. 3 HTLV-I is known to be responsible for immunodepressed patients), and also by haematological malignancies. 1 We report a case in which HTLV-I and Pneumadult T cell leukemia/lymphoma (ATL) and immunodeficiency. Transient ATL has been reported with varicella infecocystis carinii pneumonia were associated with HPS.
A 25-year-old black Caribbean man, without significant tion in an HTLV-I carrier. 4 However our patient did not have blood lymphocytosis, lymph node enlargements, skin lesions, past medical history, was admitted to the Pointe à Pitre Teaching Hospital in May 1994 with a 1 month history of dry cough, and hypercalcemia, but had lymphocytic alveolitis and liver infiltration with CD57 + T cells, a phenotype consistent with progressive dyspnea, and fever. Examination revealed a 38.5°C fever, bilateral basal crackles, no superficial lymph
LGL, and ATL cells. Some recent studies suggest that HPS could be mediated by nodes, nor hepato-splenomegaly. Chest roentgenogram demonstrated patchy, non-segmented bilateral infiltrates. WBC gamma-interferon, and macrophage colony-stimulating factor produced by T cells (CD4 or CD8), as an aberrant response was 16.2 × 10 9 /l with neutrophilia (72%). There was no liver dysfunction. Stool examination revealed Giardia lamblia but to infection. 5 Other studies have reported that HTLV-I-infected cell lines abnormally express the same cytokines. 6 The feano Strongyloides stercoralis.
The broncho-alveolar lavage fluid contained numerous tures described in our patient suggest that HTLV-I infection could have been responsible for immune suppression and P. cysts of Pneumocystis carinii and a marked increase of the lymphocytes (78%). Two HIV antibodies tests, including pepcarinii pneumonia, and for a particular (non-ATL, CD57 + ) T cell proliferation, any one of these events possibly acting, tide ELISA as well as Western blot assay, were negative. Recent infection by other viruses (Epstein-Barr virus, cytomeeither alone or in combination, to promote HPS. galovirus, herpes simplex virus, hepatitis B and C viruses) was serologically ruled out. HTLV-I IgG antibodies were detected Acknowledgements in the serum by ELISA and confirmed by Western blot. Reactivities against gag-encoded proteins p19, p24, Pr53, and also We wish to thank Pr J Diebold, Hotel-Dieu, Paris, for suggesenv-encoded gp46 and env-encoded proteins p21 were positions on the histopathological diagnosis and Dr A Gessain for tive. The initial outcome was favourable with trimethoprimreviewing this letter. sulfamethoxasole. On the 18th day after admission fever resumed and hepatomegaly was noted. Peripheral blood M Roudier 
